SUNRISE, Fla.--(BUSINESS WIRE)--Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session. Along with Dr. Povsic, Chris O'Connor, MD, Head of Heart Failure at Duke University and the study’s Principal Investigator Warren Sherman, MD, Director of Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy of Columbia University Medical Center, attended the presentation and fielded questions regarding the scientific and clinical implications of MARVEL Part 1.
